AstraZeneca (AZN,AZN.L) said results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to Imfinzi or durvalumab demonstrated a statistically significant and clinically meaningful overall survival benefit versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma or HCC who had not received prior systemic therapy and were not eligible for localised treatment.
The combination demonstrated a favourable safety profile, and the addition of tremelimumab to Imfinzi did not increase severe hepatic toxicity.
Imfinzi alone demonstrated non-inferior OS to sorafenib with a numerical trend in favour of Imfinzi and an improved tolerability profile compared to sorafenib.
Imfinzi and tremelimumab were granted Orphan Drug Designations in the US for the treatment of HCC in 2020. Tremelimumab was also granted orphan designation in the EU in HCC in 2020.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.